Novel Bifidobacterium bacteria with high bioavailability of food-derived polysaccharides

Novel Bifidobacterium pseudocatenulatum strains with a xylanase gene can metabolize xylans, addressing the lack of such strains in existing technologies and providing effective probiotics for adults by enhancing organic acid production.

KR103045254B1Active Publication Date: 2026-11-06YAKULT HONSHA KK
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
KR1020217029902
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-03-29
Filing Date
2020-03-27
Publication Date
2026-11-06
Estimated Expiration
2040-03-27

AI Technical Summary

Technical Problem

There are no known Bifidobacterium strains capable of efficiently metabolizing xylans, a major indigestible polysaccharide in adult diets, to produce short-chain fatty acids.

Method used

Isolation and identification of novel Bifidobacterium strains, specifically Bifidobacterium pseudocatenulatum strains, possessing a xylanase gene with a nucleotide sequence represented by SEQ ID NO. 1, enabling them to decompose xylans and arabinoxylans, and utilize them as a carbon source.

Benefits of technology

These strains can proliferate in adult intestines, producing high levels of organic acids, making them effective probiotics for adults in pharmaceuticals and food products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure R1020217029902_ABST
    Figure R1020217029902_ABST
Patent Text Reader

Abstract

Provides a novel Bifidobacterium strain that can utilize Xylan species. Bacteria of the genus Bifidobacterium that possess the xylanase gene on their genome.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to bacteria of the genus Bifidobacterium classified as Bifidobacterium pseudocatenulatum. Background Technology

[0002] One of the factors by which probiotics affect the physiological functions of the host is presumed to be that probiotics metabolize glycogen remaining in the digestive tract to produce short-chain fatty acids such as lactic acid and acetic acid. From previous reviews, it has become clear that the genomes of Bifidobacteria species dominant in the adult intestinal tract contain more genes related to the metabolism of plant-derived indigestible polysaccharides, particularly xylans which are abundant in the adult diet, compared to Bifidobacteria species derived from infants.

[0003] Therefore, Bifidobacterium strains with high bioavailability of indigestible polysaccharides are considered promising candidates for adult probiotics, given their expected proliferation in the adult intestines and high organic acid production capacity.

[0004] Conventionally, as Bifidobacteria capable of utilizing indigestible polysaccharides, the existence of, for example, Bifidobacterium breve strain (Non-patent Literature 1) and Bifidobacterium bifidum strain (Non-patent Literature 2) capable of magnetizing starch, and Bifidobacterium pseudocatenulatum strain (Non-patent Literature 3) capable of magnetizing arabinogalactan is known.

[0005] However, no Bifidobacteria capable of breaking down the xylose skeleton of xylans, which are major indigestible polysaccharides included in meals, have been known to date. Prior art literature

[0006] BMC Genomics (2014) 15:170 Environmental Microbiology (2015) 17(7), 2515-2531 Journal of the Japanese Society of Food Science and Microbiology, Vol.24 No.4 Page.163-170 The problem to be solved

[0007] The present invention relates to providing a novel Bifidobacterium strain capable of using Xylan species. means of solving the problem

[0008] As a result of careful examination, the inventors were able to isolate and identify a novel microbial strain capable of efficiently magnetizing xylans from the human intestine.

[0009] That is, the present invention relates to the following 1) to 9).

[0010] 1) Bacteria of the genus Bifidobacterium that have the xylanase gene on their genome.

[0011] 2) A bacterium of the genus Bifidobacterium of 1) which is a polynucleotide in which the xylanase gene consists of the nucleotide sequence represented by SEQ No. 1, or a polynucleotide that codes for a protein having xylanase activity and having at least 70% identity with said nucleotide sequence.

[0012] 3) Bifidobacterium of 1) or 2) having the ability to magnetize xylantoides.

[0013] 4) Bifidobacterium bacteria of the genus 3) which are xylans, xylans, and arabinoxylans.

[0014] 5) Any one of the Bifidobacterium bacteria 1) to 4) having the ability to magnetize starch.

[0015] 6) Bifidobacterium bacteria, any one of 1) to 5) classified as Bifidobacterium or Pseudocatenulatum.

[0016] 7) Bifidobacterium pseudocatenulatum YIT11027 (NITE BP-02928), Bifidobacterium pseudocatenulatum YIT11055 (NITE BP-02929), Bifidobacterium pseudocatenulatum YIT11057 (NITE BP-02930), Bifidobacterium pseudocatenulatum YIT11952 (NITE BP-02931), Bifidobacterium pseudocatenulatum YIT11954 (NITE BP-02932), Bifidobacterium pseudocatenulatum YIT12989 (NITE BP-02933), or strains closely related thereto.

[0017] 8) A food product containing any one of the bacteria of the genus Bifidobacterium from 1) to 7).

[0018] 9) Food product of 8) which is a fermented milk food product. Effects of the invention

[0019] The novel Bifidobacterium species related to the present invention possesses the ability to decompose and magnetize xylans, particularly arabinoxylans, which are abundant in the adult diet. Therefore, the Bifidobacterium pseudocatenulatum of the present invention is expected to proliferate in the adult intestines and produce high organic acids, and can be used as a probiotic for adults in pharmaceuticals, food products, etc. Brief explanation of the drawing

[0020] Figure 1 shows the xylose backbone cleavage activity of YIT11057. Figure 2 shows the acid and bile acid resistance of YIT11057. Specific details for implementing the invention

[0021] The bacterium of the genus Bifidobacterium of the present invention is not particularly limited as long as it has a xylanase gene on its genome. For example, Bifidobacterium pseudocatenulatum, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium animalis, Bifidobacterium suis, Bifidobacterium infantis, Bifidobacterium adolescentis, Bifidobacterium catenulatum, Bifidobacterium lactis, Bifidobacterium globosum, Bifidobacterium angulatum, Bifidobacterium dentium Any species such as (B. dentium) may be used, but preferably Bifidobacterium pseudocatenulatum is used.

[0022] Conventionally, no Bifidobacterium having a xylanase gene on its genome is known, so the Bifidobacterium genus bacteria of the present invention can be described as novel bacteria.

[0023] "Xylanase gene" refers to a gene (endo-1,4-beta-xylanase A; xynA) that codes for xylanase classified as GH10, but the "xylanase gene" possessed on the genome of the bacterium of the genus Bifidobacterium of the present invention specifically includes a polynucleotide consisting of a nucleotide sequence represented by SEQ ID NO. 1, or a polynucleotide that codes for a protein having xylanase activity and having identity with said nucleotide sequence of 70% or more, preferably 90% or more, more preferably 95% or more, more preferably 98% or more, more preferably 99% or more.

[0024] Here, the polynucleotide consisting of the base sequence represented by sequence number 1 refers to the xylanase gene possessed by the YIT11057 strain described below.

[0025] In addition, the identity of base sequences is determined by aligning the two base sequences to be compared so that as many bases as possible match, and expressing the result as a percentage by dividing the number of matching bases by the total number of bases. A person skilled in the art can determine the identity of base sequences by appropriately setting parameters of software such as BLAST, ClustalX, or Genetyx.

[0026] Also, xylanase activity refers to the activity of producing xylooligosaccharides and xylose by hydrolyzing the xylose skeleton of xylans using xylans as a substrate (xylan hydrolysis activity).

[0027] Here, as xylan types, xylan, arabinoxylan, glucuronoxylan, glucuronoarabinoxylan, acetylxylan, etc. may be used, but xylan and arabinoxylan are preferred.

[0028] Therefore, a bacterium of the genus Bifidobacterium having the xylanase gene of the present invention on its genome is, in other words, a bacterium of the genus Bifidobacterium having the ability to decompose the xylose skeleton of xylans.

[0029] In the present invention, "having the ability to magnetize xylans" means having the ability to propagate using xylans as a carbon source. Specifically, for example, it means being able to propagate in a medium in which xylans are the sole carbon source. For example, the turbidity when cultured for 72 hours in a medium in which only xylans are used as a carbon source, for example, OD 600 It refers to an increase of 0.1 or more. Turbidity is OD. 600It is preferable that the increase amount be 0.3 or higher, and more preferable that it be 0.4 or higher. In addition, in cases where changes in turbidity cannot be measured, such as in a medium supplemented with xylans containing a large amount of insoluble fraction, it refers to the production of short-chain fatty acids in the culture supernatant after 72 hours of incubation, for example, the total production amount of lactic acid, acetic acid, and formic acid being 10 mM or higher. The total production amount of short-chain fatty acids is preferably 20 mM or higher, and more preferable that it be 40 mM or higher.

[0030] As a culture medium used for testing the magnetization ability of xylans, a medium excluding sugars with added xylans may be used, and the composition of the medium excluding sugars may be M-ILS medium, Peptone-Yeast (PY) medium, etc.

[0031] The amount of Xylan added to the medium is preferably 0.01 to 10 mass%, more preferably 0.05 to 5 mass%, and even more preferably 0.1 to 1 mass%. In addition, as a control, it is desirable to culture the target Bifidobacterium genus bacteria in a medium excluding the sugar source and check the OD.

[0032] In this way, a bacterium of the genus Bifidobacterium having the xylanase gene of the present invention on its genome can contribute to the supply of short-chain fatty acids such as acetic acid, lactic acid, and formic acid produced by the decomposition of xylans, in that it has the ability to decompose xylans.

[0033] The Bifidobacterium bacteria of the present invention can be obtained by screening, for example, Bifidobacterium bacteria present in the intestines of humans (e.g., adults, infants), preferably Bifidobacterium pseudocatenulatum, using the presence of a xylanase gene or the ability to magnetize the xylans described above as indicators. For example, from Bifidobacterium pseudocatenulatum, the 16 strains shown in the later examples, and furthermore, 6 strains including YIT11027, YIT11055, YIT11057, YIT11952, YIT11954, and YIT12989, can be selected. As long as the Bifidobacterium bacteria of the present invention have a xylanase gene on their genome, they are not limited to these strains, but include strains that are biologically and genetically related to them. In addition, as long as the bacterium of the genus Bifidobacterium of the present invention has a xylanase gene on its genome, it may be a naturally occurring strain existing in nature, a variant of the naturally occurring strain, or a genetically modified variant.

[0034] YIT11027, YIT11055, YIT11057, YIT11952, YIT11954, and YIT12989 have been deposited at the Patent Microbial Depository Center of the Independent Administrative Agency for Product Evaluation Technology (Room 122, 2-5-8 Kazusakamatari, Kisarazu City, Chiba Prefecture) as of March 25, 2019, as shown below.

[0035] Bifidobacterium pseudocatenulatum YIT11027 (NITE BP-02928),

[0036] Bifidobacterium pseudocatenulatum YIT11055 (NITE BP-02929),

[0037] Bifidobacterium pseudocatenulatum YIT11057 (NITE BP-02930),

[0038] Bifidobacterium pseudocatenulatum YIT11952 (NITE BP-02931),

[0039] Bifidobacterium pseudocatenulatum YIT11954 (NITE BP-02932),

[0040] Bifidobacterium pseudocatenulatum YIT12989 (NITE BP-02933).

[0041] Among these, strains YIT11027, YIT11057, YIT11954, or closely related strains are preferred in that they possess the ability to magnetize xylans and also the ability to magnetize starches. Furthermore, strains YIT11057 or closely related strains are more preferred in that they possess acid and bile acid resistance and the characteristic that no lysogen phages are detected in the genome.

[0042] Here, starch magnetization refers to the ability to multiply using starch as a carbon source. Acid and bile acid tolerance refers to viability after continuous exposure to artificial gastric acid and artificial bile acid. The absence of lysogenic phages means that no regions with high homology to existing phages are detected in the genome sequence using the phage detection program server PHASTER (http: / / phaster.ca / ).

[0043] In addition, closely related strains refer to strains whose sequences match according to the Multilocus sequence analysis (MLSA) method, which evaluates multiple housekeeping gene sequences.

[0044] Specifically, the full sequences of DNA gyrase subunit B (gyrB), 50S ribosomal protein L2 (rplB), Amidophosphoribosyltransferase (purF), DNA-directed RNA polymerase subunit beta (rpoB), ATP-dependent Clp protease ATP-binding subunit ClpC1 (clpC), Elongation factor G (fusA), and Isoleucine-tRNA ligase (ileS), which are reported as genes suitable for MLSA analysis of Bifidobacteria (International Journal of Systematic and Evolutionary Microbiology (2006), 56, 2783-2792), are obtained, and after linking the entire genes for each strain, the sequence consistency between comparison strains is verified using a program such as VSEARCH or BLAST, and if the sequence identity is 90% or more, preferably 95% or more, more preferably 98% or more, and more preferably 99% or more, it can be determined that they are closely related species.

[0045] The nucleotide sequences of the gyrB, rplB, purF, rpoB, clpC, fusA, and ileS genes in the YIT11057 strain are shown in the sequence table (gyrB: sequence no. 2, rplB: sequence no. 3, purF: sequence no. 4, rpoB: sequence no. 5, clpC: sequence no. 6, fusA: sequence no. 7, ileS: sequence no. 8).

[0046] The form in which the Bifidobacterium bacteria of the present invention are used is not particularly limited and may be freeze-dried or used as a culture containing these bacteria, but in either form, it is preferable that the bacteria be in a live state.

[0047] The Bifidobacterium bacteria of the present invention may be mixed with a solid or liquid non-toxic carrier for pharmaceutical use and utilized in the form of conventional pharmaceutical formulations. Examples of such formulations include solid formulations such as tablets, granules, powders, and capsules; liquid formulations such as solutions, suspensions, and emulsions; and lyophilized formulations. These formulations may be prepared by conventional means of formulation. Examples of the above-mentioned non-toxic carriers for pharmaceutical use include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glycerides, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid esters, amino acids, gelatin, albumin, water, physiological saline solution, etc. Additionally, conventional additives such as stabilizers, wetting agents, emulsifiers, binders, isotonic agents, and excipients may be appropriately added as needed.

[0048] The Bifidobacterium bacteria of the present invention may be used not only as a preparation as described above, but also by being incorporated into food products. When incorporated into food products, they may be included as is or together with various nutritional components. Specifically, when incorporating the Bifidobacterium bacteria of the present invention into food products, additives suitable for use as food products may be appropriately used, and the bacteria may be molded into a form suitable for consumption, such as granules, granules, tablets, capsules, or pastes, using conventional means. Alternatively, they may be added to various foods, for example, processed meat products such as ham and sausage, processed seafood products such as fish paste and cylindrical fish paste, bread, confectionery, butter, and powdered milk, or added to beverages such as water, fruit juice, milk, soft drinks, and tea beverages. Furthermore, animal feed is also included in food products.

[0049] In addition, as a food product, fermented food products such as fermented milk products, fermented soy milk, fermented fruit juice, and fermented vegetable juice containing the Bifidobacterium genus bacteria of the present invention in a live state are preferably used, and in particular, the use of fermented milk products is preferred. The production of fermented milk products may follow conventional methods. For example, when producing fermented milk, the Bifidobacterium genus bacteria of the present invention are inoculated and cultured alone or simultaneously with other microorganisms in a sterilized milk culture medium, and this is homogenized to obtain a fermented milk base. Next, a separately prepared syrup solution is added and mixed, homogenized using a homogenizer, etc., and a flavor is added to finish the product as a final product. The fermented milk product obtained in this way may be in any form, such as a plain type that does not contain syrup (sweetener), a soft type, a fruit flavor type, a solid form, or a liquid form.

[0050] Optional ingredients such as sweeteners like syrup, emulsifiers, thickeners (stabilizers), and various vitamins may be added to these fermented milk products. As syrups, sugars such as glucose, sucrose, fructose, fructose glucose liquid sugar, glucose fructose liquid sugar, palatinose, trehalose, lactose, xylose, galactooligosaccharide (GOS), xylooligosaccharide (XOS), arabinoxyooligosaccharide (AXOS), xylan, arabinoxylan, arabinooligosaccharide (AOS), arabinan, maltose, honey, molasses, etc., sugar alcohols such as sorbitol, xylitol, erythritol, lactitol, palatinite, reduced starch syrup, reduced maltose syrup, etc., high-intensity sweeteners such as aspartame, somatin, sucralose, acesulfame K, stevia, glycerin fatty acid esters, polyglycerin fatty acid esters, sorbitan fatty acid esters, emulsifiers such as lecithin, agar, gelatin, Thickening (stabilizing) agents such as carrageenan, guar gum, xanthan gum, pectin, locust bean gum, gellan gum, carboxymethylcellulose, soybean polysaccharides, and propylene glycol alginate may be added. In addition, vitamins such as vitamin A, vitamin B, vitamin C, and vitamin E, minerals such as calcium, magnesium, zinc, iron, and manganese, acidulants such as citric acid, lactic acid, acetic acid, malic acid, tartaric acid, and gluconic acid, milk fats such as cream, butter, and sour cream, flavors such as yogurt, berry, orange, quince, perilla, citrus, apple, mint, grape, apricot, pear, custard cream, peach, melon, banana, tropical, herb, black tea, and coffee, herb extracts, brown sugar extracts, etc. may be added.

[0051] In the manufacture of fermented milk food products, microorganisms other than the Bifidobacterium bacteria of the present invention may also be used in combination. Examples of such microorganisms include Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus buchneri, Lactobacillus gallinarum, Lactobacillus amylovorus, Lactobacillus brevis, Lactobacillus rhamnosus, Lactobacillus kefir, Lactobacillus paracasei, Lactobacillus crispatus, Lactobacillus zeae, and Lactobacillus helveticus (L. Lactobacillus species such as helveticus), Lactobacillus salivalius, Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus delbrueckii subspecies, Lactobacillus delbrueckii subsp. bulgaricus, Lactobacillus delbrueckii subspecies, Lactobacillus delbrueckii subsp. delbrueckii, Lactobacillus johnsonii, Streptococcus species such as Streptococcus thermophilus, and Lactococcus lactis subspecies. Bacteria of the genus Lactococcus such as Lactis (Lactococcus lactis subsp. lactis), Lactococcus lactis subsp. cremoris, Enterococcus faecalis, and Enterococcus faecium (E.Examples include bacteria of the genus Enterococcus such as *Faecium*, bacteria of the genus Bacillus such as *Bacillus subtilis*, and yeasts belonging to the genuses Saccharomyces, Torulaspora delbrueckii, and Candida kefyr, such as *Saccharomyces cerevisiae*, *Torulaspora delbrueckii*, and *Candida kefyr*. It is desirable to manufacture a fermented milk food product by using one or more selected from bacteria of the genus Lactobacillus, Streptococcus, and Lactococcus in combination with the bacteria of the genus Bifidobacterium of the present invention, as this results in high palatability and makes the food easier to consume.

[0052] Although there are no strict limitations on the dosage when using the Bifidobacterium bacteria of the present invention, the preferred dosage is 10 per day in terms of viable bacteria count. 5 cfu ~ 10 13 It is CFU, and specifically 10 8 cfu ~ 10 12 cfu is desirable.

[0053] Examples

[0054] Example 1 Selection of Bifidobacterium bacteria having the ability to magnetize xylans

[0055] i) Strains used

[0056] Fifty-three strains isolated from human feces and identified as Bifidobacterium pseudocatenulatum were selected for screening.

[0057] ii) Temperament

[0058] Xylan (derived from oats), arabinoxylan (derived from wheat), and xylooligosaccharide (XOS), which is industrially produced by enzymatic treatment of xylan, were used for analysis. Regarding xylan and arabinoxylan, HPLC analysis confirmed no incorporation of monosaccharides (data not published). In addition, xylose and arabinose, which are the respective constituent monosaccharides, and starch, a representative indigestible polysaccharide, along with its constituent monosaccharides glucose and lactose, were also provided for analysis as controls for confirming proliferation. After preparing 1% suspensions of each substrate, xylan, arabinoxylan, and starch were autoclaved, while the other substrates were filter-sterilized using a 0.22 μm filter.

[0059] iii) Magnetization test

[0060] To prevent inhibition of bacterial growth due to a decrease in pH associated with growth, m-PY medium supplemented with 100 mM PIPES was used. An equal amount of 1% substrate solution was mixed into 2x concentrated m-PY medium, which had been refrigerated under nitrogen gas until use, and used for the culture test (species concentration 0.5%).

[0061] The frozen bacterial suspension was inoculated onto modified GAM agar medium and cultured for 2–3 days; the resulting colonies were subcultured into modified GAM liquid medium supplemented with 1% glucose and lactose. Care was taken to scrape off a large number of colonies during subculture. The culture was incubated overnight at 37°C, and the following morning, 5% of the bacterial suspension was subcultured again into fresh copper medium. After incubating for approximately 6–9 hours until reaching the logarithmic growth phase, the turbidity was measured. 100 µl of the culture medium was centrifuged to remove the supernatant, and the OD was... 600The pellet was suspended by adding m-PY medium without added glycogen to equal 0.2. 198 µl of each medium was dispensed into a 96-well plate, 2 µl of bacterial suspension was added, and 50 µl of mineral oil was added as a top layer. The plates were then incubated at 37°C in a PowerWave 340 microplate reader (Biotech).

[0062] Turbidity was measured every 30 minutes and monitored from the start of culture up to 60 hours. All of the above culture operations were performed inside an anaerobic glove box. After 60 hours, a portion of the culture medium was taken, deproteinized, and then fed to an HPLC to measure the production of short-chain fatty acids. Furthermore, in cases where a large amount of insoluble particles were detected in the xylan-added m-PY medium, cell growth could not be confirmed by measuring turbidity alone; therefore, magnetization was determined by the presence or absence of short-chain fatty acid production. Short-chain fatty acids in the culture supernatant after 60 hours of culture were measured using HPLC, and it was confirmed that the total production of lactic acid, acetic acid, and formic acid was 10 mM or more. The results regarding the extent to which various substrates could be magnetized are shown in Table 1.

[0063]

[0064] Although the utilization of xylooligosaccharides was confirmed in all strains of Bifidobacterium pseudocatenulatum, the utilization of longer-chain xylans varied among strains, and 16 strains that magnetized xylans and arabinoxylans were selected as Bifidobacterium bacteria capable of magnetizing xylans.

[0065] Bifidobacterium strains capable of magnetizing xylans were cultured in a liquid medium containing xylan as a sugar source, and the oligosaccharides in the culture supernatant during the early logarithmic growth phase were analyzed by HPLC. As a result, it was confirmed that xylose and xylooligosaccharides were produced. In this regard, it was confirmed that the bacteria possess the activity of cleaving a xylose skeleton into xylose and xylooligosaccharides. As a representative example, the analysis results using strain YIT11057, one of the 16 strains mentioned above, are shown in Figure 1. X1 to X6 in Figure 1 represent xylose and xylooligosaccharides having a number of xylose skeletons, respectively, and it can be seen that xylose and xylooligosaccharides, which could not be detected in the medium, were produced by the culture of strain YIT11057.

[0066] Example 2: Six main properties of YIT11027, YIT11055, YIT11057, YIT11952, YIT11954, and YIT12989

[0067] The magnetization of the following 6 strains, YIT11027, YIT11055, YIT11057, YIT11952, YIT11954, and YIT12989, selected from the 16 strains having the ability to magnetize the above xylans, is shown below. For the three strains YIT11027, YIT11057, and YIT11954, magnetization of starch along with magnetization of xylans could be confirmed (Table 2).

[0068]

[0069] Example 3 Genome Analysis

[0070] Genomic DNA was extracted from the cells, and a draft genome was determined using the next-generation sequencer Miseq (Illumina). After predicting the gene regions, the entire amino acid sequence was referenced to the sugar metabolism gene database dbCAN to extract sugar metabolism genes. As a result of searching for genes that matched the availability and distribution of xylanases, all strains possessing the endo-1,4-beta-xylanase A gene (xynA) belonging to GH10 were able to utilize xylanases. In addition, all strains that did not possess the same gene were unable to utilize xylanases.

[0071] Example 4 Properties of YIT11057

[0072] For YIT11057, acid and bile acid resistance, comprehensive search for pathogenic factors, and detection of lysogenic phages in the genome were evaluated.

[0073] 1) Acid and bile acid resistance

[0074] i) Composition of artificial solution

[0075] <Artificial Gastric Fluid Composition (pH 3.6)>

[0076] Pepsin 40 mg / L

[0077] Proteose peptone 5 g / L

[0078] Gastric mucin 1.5 g / L

[0079] NaCl 5 g / L

[0080] NaHCO33 g / L

[0081] KH2PO41 g / L

[0082] Adjust the pH of 3.6N HCl to 3.6.

[0083] Artificial Serum

[0084] NaCl 5 g / L

[0085] KCl 1 g / L

[0086] NaHCO33 g / L

[0087] Adjust 3M Na2CO3 pH to 8.0

[0088] ii) 0.1 ml of bacterial suspension cultured overnight in mGAM liquid medium supplemented with 1% glucose and lactose was added to 2 ml of artificial gastric fluid and incubated at 37°C for 1 hour. Afterward, 5.5 ml of artificial intestinal fluid and 0.5 ml of 16% bile acid were added and left to stand at 37°C for 1 hour. Bacterial suspensions were collected before and after acid treatment and after bile acid treatment. After dilution with physiological saline, 50 µl was plated onto mGAM agar medium to measure CFU. As a result, a survival rate of approximately 0.1% was observed even after bile acid treatment (Fig. 2). Since the CFU after each treatment was below the detection lower limit in the case of non-resistance, it was found that YIT11057 possesses relatively high resistance to acid and bile acid.

[0089] 2) Comprehensive exploration of pathogenic factors

[0090] Draft genome information was entered into the PATRIC server (https: / / www.patricbrc.org / ) (Wattam et al., 2017), and the presence of genes with high homology to sequences in the Virulence Factor database was checked. As a result, no pathogenic factor genes were detected.

[0091] 3) Detection of lysogenic phages in the genome

[0092] Regarding the genome information of the strain, we attempted to detect lysogen phages registered in the phage database using the PHASTER server (http: / / phaster.ca / ) (Arndt et al., 2016). As a result, no lysogen phages were detected.

Claims

Claim 1 A bacterium of the genus Bifidobacterium having a xylanase gene on its genome, wherein the xylanase gene is a polynucleotide consisting of the nucleotide sequence represented by SEQ No. 1, and having the ability to magnetize xylans. Claim 2 In claim 1, the xylantic bacteria are xylan and arabinoxylan. Claim 3 A bacterium of the genus Bifidobacterium having the ability to magnetize starch in claim 1 or 2. Claim 4 In claim 1 or 2, the bacterium of the genus Bifidobacterium is a bacterium of the genus Bifidobacterium classified as Bifidobacterium pseudocatenulatum. Claim 5 A strain that is Bifidobacterium pseudocatenulatum YIT11027 (NITE BP-02928), Bifidobacterium pseudocatenulatum YIT11055 (NITE BP-02929), Bifidobacterium pseudocatenulatum YIT11057 (NITE BP-02930), Bifidobacterium pseudocatenulatum YIT11952 (NITE BP-02931), Bifidobacterium pseudocatenulatum YIT11954 (NITE BP-02932), or Bifidobacterium pseudocatenulatum YIT12989 (NITE BP-02933). Claim 6 A food product containing bacteria of the genus Bifidobacterium described in claim 1 or 2, or a strain described in claim 5. Claim 7 In Article 6, a food product that is a fermented milk food product. Claim 8 delete Claim 9 delete

Citation Information

Patent Citations

  • Methods of Producing GH8 Xylanase Variants

    US20120288585A1